surmount-1 tirzepatide non-diabetic obesity weight loss 💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO trial investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with or overweight but without diabetes. Researchers Tirzepatide cuts diabetes risk by

Hence, it is essential to take your healthcare provider onboard before including any new supplement into your diet or making any kind of lifestyle alterations, especially when you are dealing with certain health conditions or are pregnant

Altogether, these important findings may pave the way to developing novel antiviral strategies for treating infectious liver disease

Protocol: Started at 0.5mg weekly (weeks 1-2), increased to 1mg weekly (weeks 3+)

While renin-angiotensin system (RAS) and sodium glucose cotransporter 2 (SGLT2) inhibitors reduce CKD progression and cardiovascular risks, residual risks remain, especially with high albuminuria

~0.7mg 1.3mg 2.7mg 3x/week 3 injections/week P/T Ratio: ~1.6 Peak Reduction: 35% 4

Medspa settings should still maintain written protocols for injectables, devices, and emergency procedures to document training and safety oversight